A. Masson-Lecomte
About
A. Masson-Lecomte is a scholar working on Surgery, Urology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, A. Masson-Lecomte has authored 87 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Surgery, 27 papers in Urology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Masson-Lecomte's work include Bladder and Urothelial Cancer Treatments (70 papers), Urinary and Genital Oncology Studies (53 papers) and Urological Disorders and Treatments (26 papers). A. Masson-Lecomte is often cited by papers focused on Bladder and Urothelial Cancer Treatments (70 papers), Urinary and Genital Oncology Studies (53 papers) and Urological Disorders and Treatments (26 papers). A. Masson-Lecomte collaborates with scholars based in France, United States and Spain. A. Masson-Lecomte's co-authors include Morgan Rouprêt, Éva Compérat, Shahrokh F. Shariat, Thomas Seisen, Bas W.G. van Rhijn, Otakar Čapoun, Paolo Gontero, Fredrik Liedberg, Hugh Mostafid and Viktor Soukup and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and European Urology.
In The Last Decade
A. Masson-Lecomte
77 papers receiving 2.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| A. Masson-Lecomte France | 18 | 1.7k | 665 | 463 | 462 | 453 | 87 | 2.2k | ||
| Ho Kyung Seo South Korea | 22 | 1.1k 0.7× | 749 1.1× | 500 1.1× | 515 1.1× | 316 0.7× | 148 | 2.1k | ||
| Marek Babjuk Czechia | 23 | 1.6k 1.0× | 378 0.6× | 424 0.9× | 478 1.0× | 541 1.2× | 93 | 2.1k | ||
| J.L. Domínguez Escrig Spain | 5 | 1.6k 0.9× | 292 0.4× | 368 0.8× | 347 0.8× | 478 1.1× | 13 | 1.8k | ||
| Harman Max Bruins Netherlands | 13 | 2.0k 1.2× | 490 0.7× | 326 0.7× | 474 1.0× | 664 1.5× | 17 | 2.2k | ||
| Joan Palou Redorta Spain | 17 | 1.3k 0.8× | 684 1.0× | 316 0.7× | 296 0.6× | 631 1.4× | 65 | 2.0k | ||
| Thomas Chromecki Austria | 24 | 1.0k 0.6× | 776 1.2× | 478 1.0× | 523 1.1× | 239 0.5× | 57 | 1.8k | ||
| Anna Orsola Spain | 26 | 1.3k 0.8× | 802 1.2× | 359 0.8× | 645 1.4× | 385 0.8× | 64 | 2.2k | ||
| Miguel Unda Spain | 19 | 1.0k 0.6× | 408 0.6× | 658 1.4× | 335 0.7× | 431 1.0× | 82 | 1.9k | ||
| Eduardo Solsona Spain | 22 | 2.8k 1.6× | 412 0.6× | 545 1.2× | 594 1.3× | 993 2.2× | 41 | 3.2k | ||
| Ilaria Lucca Switzerland | 23 | 744 0.4× | 492 0.7× | 258 0.6× | 456 1.0× | 223 0.5× | 70 | 1.4k |
Countries citing papers authored by A. Masson-Lecomte
Since
Specialization
Citations
This map shows the geographic impact of A. Masson-Lecomte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Masson-Lecomte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Masson-Lecomte more than expected).
Fields of papers citing papers by A. Masson-Lecomte
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by A. Masson-Lecomte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Masson-Lecomte. The network helps show where A. Masson-Lecomte may publish in the future.
Co-authorship network of co-authors of A. Masson-Lecomte
This figure shows the co-authorship network connecting the top 25 collaborators of A. Masson-Lecomte. A scholar is included among the top collaborators of A. Masson-Lecomte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Masson-Lecomte. A. Masson-Lecomte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gontero, Paolo, Alison Birtle, Otakar Čapoun, et al.. (2024). European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update. European Urology. 86(6). 531–549.
2.
Roumiguié, M., Priscilla Léon, Évanguelos Xylinas, et al.. (2024). Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2024–2026 : tumeurs de la vessie n’infiltrant pas le muscle (TVNIM). 34(7). F272–F295.
3.
Roumiguié, M., Thomas Seisen, A. Masson-Lecomte, et al.. (2024). French AFU Cancer Committee Guidelines – Update 2024–2026: Upper urinary tract urothelial cancer (UTUC). PubMed. 34(12). 102722–102722.
4.
Roumiguié, M., Gautier Marcq, Y. Neuzillet, et al.. (2024). French AFU Cancer Committee Guidelines – Update 2024–2026: Muscle-invasive bladder cancer (MIBC). PubMed. 34(12). 102741–102741.
5.
Roumiguié, M., Priscilla Léon, Évanguelos Xylinas, et al.. (2024). French AFU Cancer Committee Guidelines – Update 2024–2026: Non-muscle invasive bladder cancer (NMIBC). PubMed. 34(12). 102742–102742.
6.
D‘Andrea, David, Hugh Mostafid, Paolo Gontero, et al.. (2024). Unmet Need in Non–muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. European Urology Oncology. 8(1). 216–229.
7.
Pignot, G., Michaël Baboudjian, C. Lebâcle, et al.. (2023). Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure. World Journal of Urology. 41(11). 3195–3203.
8.
Rouprêt, Morgan, Thomas Seisen, Alison Birtle, et al.. (2023). European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. European Urology. 84(1). 49–64.
9.
Xylinas, Évanguelos, Arnaud Méjean, A. Masson-Lecomte, et al.. (2023). Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients. British Journal of Urology. 132(1). 56–64.
10.
Fontugne, Jacqueline, Évanguelos Xylinas, Clémentine Krucker, et al.. (2023). Transcriptomic Profiling of Upper Tract Urothelial Carcinoma: Bladder Cancer Consensus Classification Relevance, Molecular Heterogeneity, and Differential Immune Signatures. Modern Pathology. 36(11). 100300–100300.
11.
Calleris, Giorgio, Morgan Rouprêt, Thomas Seisen, et al.. (2023). Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756). World Journal of Urology. 41(12). 3413–3420.
12.
Gauthier, Hélène, Christophe Hennequin, Évanguelos Xylinas, et al.. (2023). Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer. World Journal of Urology. 41(11). 3249–3255.
13.
Masson-Lecomte, A., M. Roumiguié, Benjamin Pradère, et al.. (2022). Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee. Cancers. 14(21). 5452–5452.
14.
Audenet, François, Albert Sotto, M. Roumiguié, et al.. (2022). Recommandations des Comités de cancérologie (CC-AFU) et d’infectiologie (CI-AFU) de l’Association française d’urologie pour la prise en charge effets indésirables et complications du BCG. Progrès en Urologie. 32(3). 165–176.
15.
Neuzillet, Y., Thomas Seisen, Olivier Traxer, et al.. (2022). French AFU Cancer Committee Guidelines – Update 2022–2024: Upper urinary tract urothelial cancer (UTUC). Progrès en Urologie. 32(15). 1164–1194.
16.
Neuzillet, Y., Priscilla Léon, Thomas Seisen, et al.. (2022). A prospective descriptive 1‐year study in France of all BCG therapy dispensations for non‐muscle‐invasive bladder cancer . British Journal of Urology. 131(5). 611–616.
17.
Roumiguié, M., Éva Compérat, Léonor Chaltiel, et al.. (2020). PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment. World Journal of Urology. 39(11). 4055–4065.
18.
Pignot, G., Nadine Houédé, M. Roumiguié, et al.. (2018). Pièce opératoire ypT0N0 après séquence chimiothérapie néo-adjuvante – cystectomie pour TVIM : épidémiologie et impact pronostique. Une mise au point du CCAFU Vessie. Progrès en Urologie. 28(12). 567–574.
19.
Peyronnet, B., Z. Khene, Alexandre de la Taille, et al.. (2018). Peri‐operative and local control outcomes of robot‐assisted partial nephrectomy vs percutaneous cryoablation for renal masses: comparison after matching on radiological stage and renal score. British Journal of Urology. 123(4). 632–638.
20.
Masson-Lecomte, A., Evangelina López de Maturana, Michael E. Goddard, et al.. (2016). Inflammatory-Related Genetic Variants in Non–Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment. Cancer Epidemiology Biomarkers & Prevention. 25(7). 1144–1150.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ho Kyung Seo Breakdown of academic impact, for papers by Marek Babjuk Breakdown of academic impact, for papers by J.L. Domínguez Escrig Breakdown of academic impact, for papers by Harman Max Bruins Breakdown of academic impact, for papers by Joan Palou Redorta Breakdown of academic impact, for papers by Thomas Chromecki Breakdown of academic impact, for papers by Anna Orsola Breakdown of academic impact, for papers by Miguel Unda Breakdown of academic impact, for papers by Eduardo Solsona Breakdown of academic impact, for papers by Ilaria Lucca